UCB Group (UCBJF.PK) Release: First Assessment of Individual RLS Domains in New Post-Hoc Analyses of Neupro® Studies
4/25/2012 10:54:26 AM
ATLANTA--(BUSINESS WIRE)--New post-hoc analyses of pivotal clinical trials of Neupro® (rotigotine transdermal system) in patients with Restless Legs Syndrome (RLS)/Willis Ekbom disease analysed the severity and impact of RLS symptoms using changes in individual International RLS Study Group Rating Scale (IRLS) item scores. Improvements with rotigotine versus placebo were observed in most of the single items from the IRLS, which measures sensory-motor dysfunction, severity of sleep disturbance, and impact of RLS on daily activities. The findings from the post-hoc analyses of the two pivotal trials carried out in US and Europe were presented today at the 64th American Academy of Neurology (AAN) Annual Meeting in New Orleans, LA.